Your browser doesn't support javascript.
loading
Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
Stafford, Arielle P; Hoskin, Tanya L; Day, Courtney N; Sanders, Stacy B; Boughey, Judy C.
Affiliation
  • Stafford AP; Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Hoskin TL; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • Day CN; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • Sanders SB; Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Boughey JC; Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA. Boughey.judy@mayo.edu.
Ann Surg Oncol ; 29(8): 4740-4749, 2022 Aug.
Article in En | MEDLINE | ID: mdl-35451727
ABSTRACT

BACKGROUND:

Management of the axilla in patients with cT1-2N0 breast cancer with one or two positive (+) sentinel lymph nodes (SLNs) is often debated, especially in patients undergoing mastectomy. In 2018, the National Cancer Database (NCDB) began collecting the number of +SLNs, enabling identification of patients with one or two +SLNs for the first time.

METHODS:

From the 2018 NCDB participant user file (PUF), all cT1-2N0M0 patients with one or two +SLNs were identified. The rates of completion axillary lymph node dissection (cALND) after breast-conserving surgery (BCS) and mastectomy were determined, and logistic regression was used to assess factors associated with cALND.

RESULTS:

Of 10,531 patients with one or two +SLNs, cALND was performed in 807/6498 (12.4%) BCS patients and 1845/4033 (45.7%) mastectomy patients (p < 0.001). Factors associated with cALND in BCS were cT2 versus cT1 (16.0% versus 11.1%, p < 0.001), two versus one positive SLN (20.7% versus 10.8%, p < 0.001), and higher tumor grade (grade 3 15.4% versus grade 1-2 11.7%, p = 0.002). Factors associated with cALND among mastectomy were cT2 versus cT1 (48.2% versus 43.7%, p = 0.004), two versus one positive SLN (56.6% versus 42.8%, p < 0.001), younger age (age < 50 years 49.0%, age 50+ years 44.1%, p = 0.004), and Hispanic ethnicity (55.7% versus 45.1%, p = 0.001). After adjusting for pN category, adjuvant radiation was significantly less likely after mastectomy if cALND was performed (odds ratio (OR) 0.51, p < 0.001).

CONCLUSIONS:

Omission of cALND with one or two +SLNs in BCS is common. Deescalation of axillary therapy in mastectomy is slower, with a cALND rate of 45.7% in 2018. With the recent updates to the National Cancer Care Network (NCCN) guidelines, we anticipate continued deescalation of axillary therapy in mastectomy patients.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Sentinel Lymph Node Type of study: Guideline / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Middle aged Language: En Journal: Ann Surg Oncol Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Sentinel Lymph Node Type of study: Guideline / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Middle aged Language: En Journal: Ann Surg Oncol Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: United States